Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Recruiting
Phase 4
Interventional Study
Multiple Myeloma Refractory
Relapsed Multiple Myeloma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- CHU de Quebec-Universite Laval · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in pat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Multiple myeloma patient:
* ≥ 18 years old
* ≥ 1 prior lines of therapy
* Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
* On previous Ig support or not
Exclusion Criteria:
* Less than 18 years old
* Pregancy or breastfeeding
Contacts